SanMedica unveils new HGH-booster at Academy of Women’s Health’s Annual Congress
WASHINGTON — SanMedica International on Friday introduced its SeroVital-HGH, a new oral human-growth hormone booster formulated with women in mind, at the Academy of Women’s Health’s Annual Congress here.
"Research is revealing that growth hormone is a vital aspect of women’s health that could affect everything from obesity to skin and aging to sex drive," stated Gina Daines, SanMedica spokeswoman. "Many of the women’s health experts attending this conference have seen that research and are beginning to realize the huge potential increased HGH levels could have for the women in their care."
"We’ve been thrilled about the opportunity to share our research with the highly respected group of women’s healthcare providers who are attending the conference," added Amy Heaton, SanMedica director of Scientific Affairs. "The research behind SeroVital is not only revolutionary because it proves there’s an oral compound capable of increasing growth hormone levels naturally — without synthetic injections — but also because it was the first clinical trial of its kind to test a compound’s growth hormone boosting effects not just on young males, but on both men and women across an appropriately wide age range. We think it’s important to let women’s health experts know just how well women responded to the SeroVital complex."
Bausch + Lomb files IPO registration with SEC
ROCHESTER, N.Y. — Bausch + Lomb on Friday announced that it has filed a registration statement with the U.S. Securities and Exchange Commission to take the company public. The number of shares to be offered and the price range for the proposed offering have not yet been determined, the company stated.
The proposed IPO could raise as much as $1.5 billion and is expected to value Bausch & Lomb at about $9 billion to $10 billion, Reuters reported earlier in March.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.
SoloHealth fills new role of director of business planning and analytics
ATLANTA — SoloHealth on Friday named Joe Stephens to the newly created role of director of business planning and analytics. Stephens will focus on organizing business development initiatives, priorities, metrics and efficiencies, as well as helping guide new-business exploration as the company continues its growth.
Stephens will report directly to Stephen Kendig, chief commercial officer and EVP of SoloHealth, effective immediately.
“Joe brings a fresh and unique perspective and expertise to the SoloHealth team as we continue to rapidly scale our platform nationally and explore other strategic opportunities within the health services space,” Kendig said. “His background in sales and analytics, along with his start-up mentality, makes him a strong fit for SoloHealth.”
Prior to SoloHealth, Stephens served as the VP of business process improvement at Transcend Services for a year prior to the acquisition by Nuance Communication in April 2012. Stephens began his career as a sales engineer with Carrier Corporation in Mobile, Alabama, where he worked alongside engineers and commercial contractors in the design and layout of HVAC systems for commercial applications.
Stephens holds undergraduate degrees in electrical engineering and finance from Auburn University and an MBA focused in finance and strategic marketing from Indiana University.